SPRUCE BIOSCIENCES INC (SPRB)
US85209E1091 - Common Stock
SPRB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. The financial health of SPRB is average, but there are quite some concerns on its profitability. SPRB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SPRB has reported negative net income.
SPRB had a negative operating cash flow in the past year.
In the past 5 years SPRB always reported negative net income.
SPRB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SPRB has a Return On Assets (-46.09%) which is in line with its industry peers.
SPRB has a Return On Equity (-62.62%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.09% | ||
| ROE | -62.62% | ||
| ROIC | N/A |
ROA(3y)-44.49%
ROA(5y)-86.02%
ROE(3y)-56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SPRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRB has been increased compared to 1 year ago.
SPRB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SPRB has an improved debt to assets ratio.
2.2 Solvency
SPRB has an Altman-Z score of -2.62. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
SPRB's Altman-Z score of -2.62 is in line compared to the rest of the industry. SPRB outperforms 44.96% of its industry peers.
SPRB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
SPRB has a Debt to Equity ratio (0.02) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.62 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 4.18 indicates that SPRB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.18, SPRB is in line with its industry, outperforming 47.18% of the companies in the same industry.
A Quick Ratio of 4.18 indicates that SPRB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.18, SPRB is in line with its industry, outperforming 47.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.18 | ||
| Quick Ratio | 4.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 38.71% over the past year.
EPS 1Y (TTM)38.71%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q1.83%
3.2 Future
Based on estimates for the next years, SPRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.62% on average per year.
SPRB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.98% yearly.
EPS Next Y9.29%
EPS Next 2Y8.89%
EPS Next 3Y3.83%
EPS Next 5Y17.62%
Revenue Next Year-46.28%
Revenue Next 2Y-46%
Revenue Next 3Y133.62%
Revenue Next 5Y53.98%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SPRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.89%
EPS Next 3Y3.83%
5. Dividend
5.1 Amount
No dividends for SPRB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SPRUCE BIOSCIENCES INC
NASDAQ:SPRB (5/17/2024, 7:00:03 PM)
After market: 0.7501 +0 (+0.01%)0.75
-0.02 (-2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap30.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.09% | ||
| ROE | -62.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.18 | ||
| Quick Ratio | 4.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)38.71%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y9.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y